Drug intelligence / Profile preview

Y200

Development stage: Preclinical
Lead developer: Atticus Pharma
Modality: Small Molecules
Administration: Topical

Overview

Y200 is a Terminalia chebula extract developed by Yuva Biosciences and licensed exclusively worldwide to Atticus Pharma for pharmaceutical applications. Atticus Pharma, a spin-out from Zylö, is developing Y200 for the treatment of alopecia and wound-healing, utilizing its proprietary Z-pod topical delivery technology. The Z-pod technology, based on silica-derived particles, enables sustained topical delivery of active ingredients.

Beyond the preview

Go deeper on Y200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Y200.

Explore the full profile